Cargando…

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides

The emergence and rapid spreading of SARS-CoV-2 variants of concern (VOCs) have posed a great challenge to the efficacy of vaccines and therapeutic antibodies, calling for antivirals that can overcome viral evasion. We recently reported that SARS-CoV-2 fusion-inhibitory lipopeptides, IPB02V3 and IPB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yuanmei, Hu, Yue, Liu, Nian, Chong, Huihui, He, Yuxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574594/ https://www.ncbi.nlm.nih.gov/pubmed/36265805 http://dx.doi.org/10.1016/j.antiviral.2022.105445

Ejemplares similares

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor
por: Hu, Yue, et al.
Publicado: (2022)

Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2
por: Zhu, Yuanmei, et al.
Publicado: (2023)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages
por: Wang, Yuliang, et al.
Publicado: (2023)

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
por: Schmitz, Katharina S., et al.
Publicado: (2022)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
por: Park, Young-Jun, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
por: Ren, Ping, et al.
Publicado: (2023)

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
por: Ren, Ping, et al.
Publicado: (2023)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
por: Gruell, Henning, et al.
Publicado: (2022)

Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart
por: Girardi, Viviane, et al.
Publicado: (2023)

Continued Complexity of Mutations in Omicron Sublineages
por: Spratt, Austin N., et al.
Publicado: (2022)

Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
por: de Vries, Rory D., et al.
Publicado: (2020)

Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
por: de Vries, Rory D., et al.
Publicado: (2021)

Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
por: Li, Xiaoman, et al.
Publicado: (2022)

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Preparation and evaluation of amphipathic lipopeptide‐loaded PLGA microspheres as sustained‐release system for AIDS prevention
por: Jin, Huijuan, et al.
Publicado: (2020)

Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
por: Wang, Yizhen, et al.
Publicado: (2023)

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides
por: Hu, Yue, et al.
Publicado: (2023)

Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages
por: Wang, Lei, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates
por: Mathieu, Cyrille, et al.
Publicado: (2018)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
por: Li, Qianqian, et al.
Publicado: (2022)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis
por: Relan, Pryanka, et al.
Publicado: (2023)

Renaming the SARS‐CoV‐2 Omicron sublineages as SARS‐CoV‐3 is contrary to nomenclature standards based on evolutionary and serological evidence
por: Qi, Zhongtian, et al.
Publicado: (2022)

Genome Sequences of 25 SARS-CoV-2 Sublineage B.1.1.529 Omicron Strains in Bangladesh
por: Bin Manjur, Omar Hamza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ueshr9sq1sddrgv7pbrhfj0h10